Skip to content

Frozen Blastocyst Transfer Using Conventional Timing Versus Timing by Endometrial Receptivity Analysis

A Randomized Controlled Trial Comparing Live Birth From Single, Euploid Frozen Blastocyst Transfer Using Conventional Timing Versus Timing by Endometrial Receptivity Analysis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03558399
Acronym
Synchrony
Enrollment
800
Registered
2018-06-15
Start date
2018-04-25
Completion date
2021-09-23
Last updated
2020-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Implantation Failure, Infertility, Female

Keywords

Endometrial receptivity analysis, Window of implantation, Euploid, Infertility, Female, Implantation failure, Frozen embryo transfer FET, ERA, WOI, FET, Synchrony

Brief summary

To assess live birth after embryo transfer according to an individual's ERA results as opposed to routine protocol for frozen embryo transfer (FET) cycles.

Detailed description

It has been proposed, that the receptivity status of the endometrium shifts among individual women and that repeated implantation failure is ascribable to an endometrial factor in up to 25%. The endometrial receptivity analysis (ERA) is a diagnostic method that was developed based on the unique genomic signature of the endometrium during the window of implantation and classifies the endometrium as receptive, pre-receptive or post-receptive to guide embryo transfer. The purpose of this assessor-blind, randomized clinical study is to determine whether live birth from vitrified/thawed euploid embryo transfer is improved when transfer is timed according to endometrial receptivity analysis (ERA) results. Approximately 800 women (n=400 in each arm) will be enrolled according to the inclusion/exclusion criteria among patients of Shady Grove Fertility. Participants will undergo a standard in vitro fertilization (IVF) cycle, followed by preimplantation genetic screening (PGS) provided a high quality blastocyst is available. Participants with at least one PGS normal (euploid) embryo will be randomized (assigned by chance, like the flip of a coin) to one of two study groups. Women in both study arms will then undergo ERA testing and neither the patients nor their treating physicians will know to which group the women have been assigned to, or the ERA testing results. Up until this point there is no difference between the study and control group. The investigational aspect of this trial is described as follows: If the participant is assigned to the study arm, the single, euploid, frozen embryo transfer (FET) during the subsequent cycle will be performed at the time indicated by the ERA test results. If she is in the control arm, the embryo will be transferred according to our standard FET protocol. Patients enrolling in the study will receive PGS and ERA free of charge.

Interventions

OTHERFET according to ERA

Single euploid FET will be performed at the time indicated by the ERA test results.

OTHERFET according to standard protocol

Single euploid FET will be performed according to our standard FET protocol.

Sponsors

Igenomix
CollaboratorINDUSTRY
Shady Grove Fertility Reproductive Science Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Masking description

Results of the ERA analysis will not be disclosed to the patient or the physician or the outcome assessor, nor will the study arm to which the patient was assigned, though the patient/physician may be able to intuit assignment to the ERA arm based on the frozen embryo transfer time that she is assigned. The date and time of embryo transfer will be provided by the investigator/research team.

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. Signed informed consent 2. Female age between 30 and 40 years and deemed likely by her physician, based on ovarian reserve testing, to produce at least one euploid blastocyst via one IVF/intracytoplasmatic sperm injection (ICSI) cycle 3. Having ≥ 1 euploid embryo available for embryo transfer 4. Standard eligibility criteria to undergo IVF and FET at Shady Grove Fertility Center.

Exclusion criteria

1. Known uterine factor impacting the endometrium 2. Use of surgically aspirated sperm for fertilization 3. Presence of any clinically relevant systemic disease that contraindicates assisted reproductive technology. 4. Since the subject last had a live birth (if any), there have been more than two embryo transfers that have not resulted in ongoing pregnancy 5. Body mass index \>40 kg/m2 at screening 6. Recurrent pregnancy loss, defined as two or more clinical pregnancy losses without live birth 7. Planned testing of embryos for single gene disorder(s) or structural chromosome rearrangements 8. Currently breast feeding, pregnant, or contraindication to pregnancy

Design outcomes

Primary

MeasureTime frame
The primary outcome measure of this clinical trial is to assess live birth after euploid embryo transfer according to an individual's ERA result as opposed to routine protocol for frozen embryo transfer (FET) cycles.From date of randomization until live born infant at an estimated gestational age of at least 23 weeks or greater

Secondary

MeasureTime frameDescription
A secondary outcome measure of this clinical trial is to assess ongoing implantation rate after embryo transfer according to an individual's ERA result as opposed to routine protocol for frozen embryo transfer (FET) cycles.From date of randomization until 7-8 weeks estimated gestational ageThe ongoing implantation rate is defined as maximum number of fetal heartbeats divided by total number of embryos transferred
A secondary outcome measure of this clinical trial is to assess implantation rate after embryo transfer according to an individual's ERA result as opposed to routine protocol for frozen embryo transfer (FET) cycles.From date of randomization until 5-6 weeks estimated gestational ageThe implantation rate is defined as the maximum number of gestational sacs per patient
A secondary outcome measure of this clinical trial is to assess biochemical pregnancy after embryo transfer according to an individual's ERA result as opposed to routine protocol for frozen embryo transfer (FET) cycles.From date of randomization until ~10 days following embryo transferBiochemical pregnancy is defined as detection of beta hCG above 5 IU/L
A secondary outcome measure of this clinical trial is to assess clinical pregnancy after embryo transfer according to an individual's ERA result as opposed to routine protocol for frozen embryo transfer (FET) cycles.From date of randomization until 5-7 weeks estimated gestational ageThe clinical pregnancy rate is defined as the presence of gestational sacs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026